{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:53Z","timestamp":1793666753335,"version":"4.5.1"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Recent advances in hematology-oncology have pioneered cell-mediated elimination of pathologic B-cell populations employing chimeric antigen receptor (CAR) T cells. In this review, we discuss recent adoption of CAR-T treatment for severe refractory autoimmune disease. We highlight unique aspects of the autoimmune model and review current clinical data regarding treatment of rheumatologic disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>To date, several CAR-Ts are FDA approved for Multiple Myeloma and B-cell malignancies and have demonstrated extraordinary clinical responses in refractory disease. Realizing the central role of B-cells in certain autoimmune diseases, CAR-T is now being explored for achieving drug-free remission induction, and potentially cure, of several rheumatologic diseases. The largest experience to date in the field of autoimmunity, building off the University Hospital Erlangen groups\u2019 earlier success treating a single patient with CD19-CAR in severe refractory SLE, Mackensen <jats:italic toggle=\"yes\">et al.<\/jats:italic> enrolled five patients in a compassionate use program. Following autologous CD19-CAR T infusion, they demonstrated drug-free clinical and laboratory remission for at least 12\u200amonths in all five patients, with reconstitution of B cells expressing a na\u00efve phenotype.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>CAR-T treatment has shown striking drug-free responses in severe lupus and other autoimmune diseases, creating a need for further exploration and development.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001012","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T15:01:20Z","timestamp":1711119680000},"page":"176-183","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Chimeric antigen receptors: \u201cCARs\u201d in the fast lane for rheumatology"],"prefix":"10.1097","volume":"36","author":[{"given":"Nathan M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Koumpouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1753-4887.1989.tb02747.x","article-title":"As based upon physiological and pathological histology: cellular pathology","volume":"47","author":"Virchow","year":"1863","journal-title":"Nutr Rev"},{"key":"R2-20250526","first-page":"385","article-title":"Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"J Exp Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans \u2014 immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N Engl J Med"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","article-title":"Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective","volume":"90","author":"Hoover","year":"2016","journal-title":"Kidney Int"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/ndt\/gfl208","article-title":"Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?","volume":"21","author":"Grootscholten","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2020-217200","article-title":"Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework","volume":"79","author":"Zhao","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"e2320851","DOI":"10.1001\/jamanetworkopen.2023.20851","article-title":"Comparative effectiveness of adalimumab vs tofacitinib in patients with rheumatoid arthritis in Australia","volume":"6","author":"Deakin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"R25-20250526","first-page":"1","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies","author":"Taubmann","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood-2023-180547","article-title":"CD19-targeted CAR-T cells in refractory systemic autoimmune diseases: a monocentric experience from the first fifteen patients","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41409-023-02086-1","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study","volume":"58","author":"Wang","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41409-023-02084-3","article-title":"Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders","volume":"58","author":"Bachanova","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-19-3579","article-title":"PET reporter gene imaging and ganciclovir-mediated ablation of chimeric antigen receptor T cells in solid tumors","volume":"80","author":"Murty","year":"2021","journal-title":"Cancer Res"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, nonrandomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R51-20250526","first-page":"1561965","article-title":"Deep serological profiling of SLE patients treated with anti-CD19 4-1BBz CAR T-cells","author":"Basu","year":"2023","journal-title":"ACR Convergence"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/annrheumdis-2023-eular.3736","article-title":"OP0141 long term safety and efficacy of CAR-T cell treatment in refractory systemic lupus erythematosus-data from the first seven patients","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"R62-20250526","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.39503","article-title":"MEDI-551 treatment effectively depletes B cells and reduces serum titers of autoantibodies in mice transgenic for Sle1 and human CD19","volume":"68","author":"Gallagher","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/art.40656","article-title":"Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease","volume":"70","author":"Streicher","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:07Z","timestamp":1748294287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001012","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}